This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign in
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Discover more about the risk factors associated with disease severity, comorbidities and resistance in CAP and cSSTI

Risk of mortality in patients with infections increases with older age, the presence of comorbidities, disease severity and delayed initiation of appropriate antimicrobial therapy/ treatment failure5,7,12,17,19,23,28–31

Dr Matthew Dryden

In this short video recorded at EAHP in 2018, Matthew Dryden discusses key considerations in managing complex patients with cSSTI and CAP using two patient case studies. 

Initial treatment choice is key to success in patients with CAP or cSSTI, and initial treatment failure is more common in patients with comorbidities17

Explore More

Read several CAP patient profiles describing potential scenarios where Zinforo could be a treatment of choice.

Access CAP patient profiles

Read several cSSTI patient profiles describing potential scenarios where Zinforo could be a treatment of choice. 

Access cSSTI patient profiles


​​​​Abbreviations
​​​​​​​
CAP, community-acquired pneumonia; COPD, chronic obstructive pulmonary disease; cSSTI, complicated skin and soft tissue infections; CURB-65, Confusion, blood Urea, Respiratory rate, Blood pressure, age >65; ICU, intensive care unit; MRSA, methicillin-resistant Staphylococcus aureus; PNSP, penicillin non-susceptible Streptococcus pneumoniae; PORT, Pneumonia Patient Outcomes Research Team; PVD, peripheral vascular disease.
Prescribing Information

Zinforo® (ceftaroline fosamil)
Great Britain
Zinforo 600 mg powder for concentrate for solution for infusion
Northern Ireland
Zinforo 600 mg powder for concentrate for solution for infusion 
​​​​​​​
Dalacin C (clindamycin hydrochloride) 150mg capsules
Dalacin C (clindamycin hydrochloride) 75mg capsules
Dalacin C (clindamycin phosphate)  sterile solution for injection
Dalacin T (clindamycin phosphate) 1% topical lotion
Dalacin (clindamycin phosphate) 2% cream
​​​​​​​
References
  1. ZINFORO. Summary of Product Characteristics
  2. Horita N, et al. Sci Rep 2015;5:14061
  3. Prina E, et al. Lancet 2015;386:1097–108
  4. Ramani A,  et al. J Chemother 2014;26:229–34
  5. Welte T, et al.Thorax 2012;67:71–9
  6. File TM, et al. Clin Infect Dis 2010;51:1395–405
  7. British Thoracic Society Community Acquired Pneumonia in Adults Guideline Group. Thorax 2009;64(SupplIII):iii1–iii55
  8. Eckmann C, et al. Eur J Med Res 2010;15:554–63
  9. Marwick C, et al. J Antimicrob Chemother 2011;66:387–97
  10. Cooke FJ, et al. Br Med Bull 2010;94:215–27
  11. Mannino DM, et al.Davis KJ, Kiri VA. Respir Med 2009;103:224–9
  12. Udeani G, et al. Hosp Prac 2014;42:109–15
  13. Luna CM, et al. Ann Am Thorac Soc 2016;13:1519–26
  14. Rajan S. Cleve ClinJ Med 2012;79:57–66
  15. Corey GR, et al. J Antimicrob Chemother 2010;65(Suppl4):iv41–iv51
  16. Amara S, et al. CurrMed Res Opin 2013;29:869–77
  17. Garau J, et al. Clin Microbiol Infect 2013;19:E377–E385
  18. Evans JD, et al. Postgrad Med 2014;126:128–34
  19. Dryden M, et al. Clin Microbiol Infect 2015;21:S27–S32
  20. Dryden M, et al. J Antimicrob Chemother 2016;71:3575–84
  21. Garcia-Vidal C, et al. Clin Microbiol Infect 2009;15:1033–8
  22. Alberti S, et al. Clin Infect Dis 2012;54:470–8
  23. Caballero J, et al. Ann Intensive Care 2011;1:48
  24. Dryden M, et al. J Antimicrob Chemother 2010;65(Suppl3):iii35–iii44
  25. Poulakou G, et al. Curr Opin Infect Dis 2017;30:158–71
  26. Mpenge MA, et al.Ther Clin Risk Manag 2015;11:565–79
  27. Augustine S, et al.Eur J Microbiol Immunol 2011;3:190–7
  28. Stupka J E, et al. Aging Health 2009;5:763–74
  29. Kothe H, et al. Eur Respir J 2008;32:139–46
  30. Garau J, et al. BMC Infect Dis 2015;15:78
  31. Edelsberg J, et al. Infect Control Hosp Epidemiol 2008;29:160–9
PP-ZFO-GBR-0230. September 2021

Tolerability profile of Zinforo

Access data on the tolerability profile of Zinforo as established in key Phase III cinical trials. 

View tolerability profile 

** This is an optional area where footnotes can live.

CAPTURE study

To learn more about the efficacy of Zinforo in a real-world setting, explore the CAPTURE study.

View CAPTURE study data

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?